Literature DB >> 19157988

SPORCalc: A development of a database analysis that provides putative metabolic enzyme reactions for ligand-based drug design.

James Smith1, Viktor Stein.   

Abstract

Understanding both the enzyme reactions that contribute to intermediate metabolism and the biochemical fate of candidate therapeutic and toxic agents are essential for drug design. Traditional metabolic databases indicate whether reactions have been observed but do not provide the likelihoods of reactions occurring, for example those of mixed function oxygenases and oxidases, during phase I metabolism. The desire for more quantitative predictions motivated the development of the recently introduced Substrate Product Occurrence Ratio Calculator (SPORCalc) that identifies metabolically labile atom positions in candidate compounds. This paper describes a further development and provides a clearer explanation of SPORCalc for the computational pharmacology, medicinal chemistry and drug design communities interested in metabolic prediction of xenobiotics using chemical databases of biotransformations. Examples of reaction centre detection in Metabolite are described followed by a demonstration of almokalant, an anti-arrhythmic agent, undergoing phase I metabolism. In general, occurrence ratio (OR) values are calculated throughout a compound and its transformed metabolites to give propensity (p) values at each atom position. The OR values from substrates and products in the database are essential for addition and elimination reactions. For almokalant, the resulting p values ranged from 10(-1) to 10(-5) and their order of magnitude reflected the known and experimentally observed metabolites. SPORCalc depends entirely on the level of detail from isoform- or species-specific reaction classes in Metabolite. Labile atom positions (sites of metabolism) are identified in both the candidate compound and its metabolites. In general, the likelihood of one enzyme isoform-dependent reaction occurring relative to another and the putative metabolic routes from different isoforms can be investigated. SPORCalc can be developed further to include suitable three-dimensional, structure-activity and physiochemical information.

Mesh:

Substances:

Year:  2008        PMID: 19157988     DOI: 10.1016/j.compbiolchem.2008.11.002

Source DB:  PubMed          Journal:  Comput Biol Chem        ISSN: 1476-9271            Impact factor:   2.877


  5 in total

1.  RS-Predictor models augmented with SMARTCyp reactivities: robust metabolic regioselectivity predictions for nine CYP isozymes.

Authors:  Jed Zaretzki; Patrik Rydberg; Charles Bergeron; Kristin P Bennett; Lars Olsen; Curt M Breneman
Journal:  J Chem Inf Model       Date:  2012-05-29       Impact factor: 4.956

2.  RS-predictor: a new tool for predicting sites of cytochrome P450-mediated metabolism applied to CYP 3A4.

Authors:  Jed Zaretzki; Charles Bergeron; Patrik Rydberg; Tao-wei Huang; Kristin P Bennett; Curt M Breneman
Journal:  J Chem Inf Model       Date:  2011-06-15       Impact factor: 4.956

Review 3.  Advantages of Structure-Based Drug Design Approaches in Neurological Disorders.

Authors:  Murali Aarthy; Umesh Panwar; Chandrabose Selvaraj; Sanjeev Kumar Singh
Journal:  Curr Neuropharmacol       Date:  2017-11-14       Impact factor: 7.363

4.  RD-Metabolizer: an integrated and reaction types extensive approach to predict metabolic sites and metabolites of drug-like molecules.

Authors:  Jiajia Meng; Shiliang Li; Xiaofeng Liu; Mingyue Zheng; Honglin Li
Journal:  Chem Cent J       Date:  2017-07-18       Impact factor: 4.215

5.  Synthesis of new Schiff bases bearing 1,2,4-triazole, thiazolidine and chloroazetidine moieties and their pharmacological evaluation.

Authors:  Nadia G Kandile; Mansoura I Mohamed; Hind M Ismaeel
Journal:  J Enzyme Inhib Med Chem       Date:  2016-10-21       Impact factor: 5.051

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.